PARIS, April 27, 2016 /PRNewswire/ --

MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces the appointment of Catherine Moukheibir as Chairman of its Board of Directors.

Catherine will succeed MedDay's previous Chairman, Jean Jacques Garaud, who contributed to the rapid development of the Company since 2013. The change is effective immediately.

Catherine started her career in strategy consulting and investment banking in Boston and London.  She held C-Suite level roles in some of Europe's leading biotechnology companies.  She is currently a member of the management board of Innate Pharma, Chairman of Creabilis and Non-Executive Director at Ablynx, Zealand Pharma and Cerenis.

Commenting on the appointment, Frédéric Sedel, CEO of MedDay, said: "I am delighted to welcome Catherine to MedDay and at the same time would like to thank Jean Jacques Garaud for his exceptional contribution to the earlier stages of the Company's development. Catherine now brings broad corporate and financial experience to our team and will boost MedDay at a significant time given our late-stage product development activity, our growing revenue stream and our ambitions for growing the business."  

Catherine Moukheibir commented: "There is currently no drug approved for non-active progressive MS and MedDay is planning to start its Phase 3 confirmatory study in the US which could potentially show the Company has a game-changing product to treat this debilitating condition.  In a relatively short amount of time, the team, supported by committed investors and the Board Directors, has created a highly impressive biotech business that is now ready to implement an international strategy for long-term success.  I am very excited to be involved at this important time and look forward to working with the team and Board on the next phase of MedDay's growth."

About MedDay 

MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer); and Guillaume Brion, MD (Chief Operating Officer). The Company's most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis. MedDay is well funded by investors including Sofinnova Partners, InnoBio, Edmond de Rothschild Investment Partners and Bpifrance Large Venture. For more information, please see: http://www.medday-pharma.com.

For more information, please contact:

MedDay Pharmaceuticals
Email: contact@medday-pharma.com

Consilium Strategic Communications
Mary-Jane Elliott, Jonathan Birt, Laura Thornton
Tel: +44(0)20-3709-5700
Email: medday@consilium-comms.com

SOURCE MedDay